CardiAQ allocates $6.5M for mitral valve implantation research

Kaitlyn Dmyterko | | Cardiovascular Business | Structural Heart Disease
In order to clinically investigate its Transcatheter Mitral Valve Implantation (TMVI) system, CardiAQ Valve Technologies has doled out $6.5 million for research.

According to the Winchester, Mass.-based company, funding was led by Rob Michiels and incorporates conversion of all previous debt to study the TMVI technology. The system is used as a non-surgical alternative for patients with functional mitral regurgitation and who are too sick to undergo surgery, according to CardiAQ.

Kaitlyn Dmyterko

Related Content

Treating younger patients with TAVR increases risk of death
Self-expanding vs. balloon-expandable TAVR valves: How they compare after 5 years
New data put a spotlight on troubling TAVR trends
How robotic-assisted mitral valve repair compares to conventional surgery
Tricuspid TEER shows clinical efficacy for first time in newest TRILUMINATE data
Cardiology societies push Medicare to pay for tricuspid TEER

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup